PARP1 and B-cell chronic lymphocytic leukemia: However, encouragingly, our data show that, in an albeit limited number of ex vivo cultures, CLL cells were sensitive to talazoparib cytotoxicity independent of their p53, ATM or HRR status, confirming that PARP is a therapeutic target in CLL.